124 related articles for article (PubMed ID: 24953334)
21. KNK437, abrogates hypoxia-induced radioresistance by dual targeting of the AKT and HIF-1α survival pathways.
Oommen D; Prise KM
Biochem Biophys Res Commun; 2012 May; 421(3):538-43. PubMed ID: 22521642
[TBL] [Abstract][Full Text] [Related]
22. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay.
Marampon F; Gravina GL; Zani BM; Popov VM; Fratticci A; Cerasani M; Di Genova D; Mancini M; Ciccarelli C; Ficorella C; Di Cesare E; Festuccia C
Int J Oncol; 2014 Jun; 44(6):2121-31. PubMed ID: 24676782
[TBL] [Abstract][Full Text] [Related]
24. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma.
Sheehan JP; Shaffrey ME; Gupta B; Larner J; Rich JN; Park DM
Future Oncol; 2010 Oct; 6(10):1591-601. PubMed ID: 21062158
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Anderson HJ; Galileo DS
Cell Oncol (Dordr); 2016 Jun; 39(3):229-42. PubMed ID: 26883759
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
27. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
28. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
29. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
[TBL] [Abstract][Full Text] [Related]
30. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.
Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H
Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618
[TBL] [Abstract][Full Text] [Related]
31. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.
Skuli N; Monferran S; Delmas C; Lajoie-Mazenc I; Favre G; Toulas C; Cohen-Jonathan-Moyal E
Cancer Res; 2006 Jan; 66(1):482-9. PubMed ID: 16397264
[TBL] [Abstract][Full Text] [Related]
32. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
33. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019.
Vecchio D; Daga A; Carra E; Marubbi D; Baio G; Neumaier CE; Vagge S; Corvò R; Pia Brisigotti M; Louis Ravetti J; Zunino A; Poggi A; Mascelli S; Raso A; Frosina G
Int J Cancer; 2014 Jul; 135(2):479-91. PubMed ID: 24443327
[TBL] [Abstract][Full Text] [Related]
34. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.
Velpula KK; Bhasin A; Asuthkar S; Tsung AJ
Cancer Res; 2013 Dec; 73(24):7277-89. PubMed ID: 24148623
[TBL] [Abstract][Full Text] [Related]
35. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis.
Ye T; Wei X; Yin T; Xia Y; Li D; Shao B; Song X; He S; Luo M; Gao X; He Z; Luo C; Xiong Y; Wang N; Zeng J; Zhao L; Shen G; Xie Y; Yu L; Wei Y
Breast Cancer Res Treat; 2014 Feb; 143(3):435-46. PubMed ID: 24398778
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
38. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance?
Hovinga KE; Stalpers LJ; van Bree C; Donker M; Verhoeff JJ; Rodermond HM; Bosch DA; van Furth WR
J Neurooncol; 2005 Sep; 74(2):99-103. PubMed ID: 16193379
[TBL] [Abstract][Full Text] [Related]
39. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
40. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
